We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.

Delisted

GBT was delisted on the 4th of October, 2022.

134 hedge funds and large institutions have $1.03B invested in Global Blood Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 64 increasing their positions, 25 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 25

106% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 18

51% more call options, than puts

Call options by funds: $14M | Put options by funds: $9.27M

16% more funds holding

Funds holding: 116134 (+18)

11% less capital invested

Capital invested by funds: $1.16B → $1.03B (-$127M)

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

Holders
134
Holders Change
+18
Holders Change %
+15.52%
% of All Funds
3.34%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.12%
New
37
Increased
64
Reduced
25
Closed
18
Calls
$14M
Puts
$9.27M
Net Calls
+$4.73M
Net Calls Change
-$850K
Name Holding Trade Value Shares
Change
Change in
Stake
Citigroup
51
Citigroup
New York
$2.4M +$2.26M +75,980 +642%
CS
52
Candriam SCA
Luxembourg
$2.27M +$179K +6,000 +8%
Invesco
53
Invesco
Georgia
$2.05M +$2.23M +75,045 New
CCM
54
Century Capital Management
Massachusetts
$1.88M -$1.52M -51,104 -43%
OAM
55
Oxford Asset Management
United Kingdom
$1.86M -$1.5M -50,409 -43%
California State Teachers Retirement System (CalSTRS)
56
California State Teachers Retirement System (CalSTRS)
California
$1.79M +$771K +25,900 +66%
MC
57
Marcus Capital
Illinois
$1.79M +$397K +13,350 +26%
UBS Group
58
UBS Group
Switzerland
$1.79M +$837K +28,120 +76%
SCA
59
Secor Capital Advisors
New York
$1.77M +$1.93M +64,792 New
JGC
60
J. Goldman & Co
New York
$1.6M +$1.74M +58,600 New
Millennium Management
61
Millennium Management
New York
$1.52M +$363K +12,203 +28%
NI
62
Numeric Investors
Massachusetts
$1.5M +$1.63M +54,800 New
EU
63
Emory University
Georgia
$1.44M +$1.57M +52,709 New
Swiss National Bank
64
Swiss National Bank
Switzerland
$1.43M
Bessemer Group
65
Bessemer Group
New Jersey
$1.37M +$1.49M +50,009 New
GC
66
Guggenheim Capital
Illinois
$1.3M +$1.41M +47,547 New
B
67
Bailard
California
$1.25M +$1.36M +45,700 New
Russell Investments Group
68
Russell Investments Group
United Kingdom
$1.2M +$454K +15,253 +53%
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
$1.14M +$675K +22,670 +118%
Creative Planning
70
Creative Planning
Kansas
$1.14M +$1.21M +40,600 +3,381%
HTC
71
Hershey Trust Company
Pennsylvania
$1.14M +$1.24M +41,675 New
Ameriprise
72
Ameriprise
Minnesota
$1.11M -$7.38K -248 -0.6%
OM
73
Opaleye Management
Massachusetts
$1.09M +$1.19M +40,000 New
New York State Common Retirement Fund
74
New York State Common Retirement Fund
New York
$1.08M +$595K +20,012 +103%
AA
75
ALPS Advisors
Colorado
$1.08M +$85.5K +2,874 +8%

GBT Hedge Fund Activity: Q2 2017 in Review

134 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2017, worth a combined $1.03B — down 11% from $1.16B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new GBT positions and 18 closed out — a net gain of 19 holders — while 64 added to existing stakes and 25 trimmed.

The largest buyer was State Street, adding an estimated $43.6M. The largest seller was White Square Capital, exiting entirely with an estimated $53.6M sold.

  • 134 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2017, up from 116 in Q1 2017.
  • Funds reported $1.03B of Global Blood Therapeutics, Inc. stock for Q2 2017, down 11% quarter-over-quarter.
  • 37 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2017 and 18 closed out, a net change of +19 holders.
  • The largest Global Blood Therapeutics, Inc. buyer in Q2 2017 was State Street, an estimated $43.6M added.
  • The largest Global Blood Therapeutics, Inc. seller in Q2 2017 was White Square Capital, an estimated $53.6M sold.

Based on aggregated 13F filings for Q2 2017.